Cargando…

Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?

Detalles Bibliográficos
Autores principales:	Merlano, Marco C, Garrone, Ornella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012560/ https://www.ncbi.nlm.nih.gov/pubmed/29942669 http://dx.doi.org/10.1136/esmoopen-2018-000404

Ejemplares similares

High incidence of cetuximab-related infusion reactions in head and neck patients
por: Palomar Coloma, Virginia, et al.
Publicado: (2018)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Immune-related response criteria: light and shadows
por: Merlano, Marco, et al.
Publicado: (2016)

Allergic/infusion reactions reported with cetuximab and rituximab
por: Wolf, Ray A, et al.
Publicado: (2015)

Retrospective analysis of premedication, glucocorticosteroids, and H(1)-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer
por: Ikegawa, Kiwako, et al.
Publicado: (2017)

Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab
por: Enokida, Tomohiro, et al.
Publicado: (2016)

ASCO highlights podcast: head and neck cancers
por: Merlano, Marco
Publicado: (2016)

Immunotherapy in Head and Neck Squamous Cell Cancer
por: Denaro, Nerina, et al.
Publicado: (2018)

How I treat squamous ENT cancer
por: Merlano, Marco Carlo, et al.
Publicado: (2019)

Management of infusion reactions associated with cetuximab treatment: A case report
por: Ohshita, Naohiro, et al.
Publicado: (2017)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab
por: Foley, K. A., et al.
Publicado: (2010)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer
por: Bouhaddou, Mehdi, et al.
Publicado: (2021)

Heterogeneity of colon cancer: from bench to bedside
por: Merlano, Marco C, et al.
Publicado: (2017)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Incidence and Management of Olaratumab Infusion-Related Reactions
por: Van Tine, Brian A., et al.
Publicado: (2019)

Dysphagia in Head and Neck Cancer Patients: Pretreatment Evaluation, Predictive Factors, and Assessment during Radio-Chemotherapy, Recommendations
por: Denaro, Nerina, et al.
Publicado: (2013)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy
por: Maahs, Lucas, et al.
Publicado: (2022)

Successful rechallenge with cetuximab after an infusion related reaction to panitumumab in a patient with locally advanced rectal cancer
por: Yokokawa, Hideyuki, et al.
Publicado: (2020)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Head and neck cancer: improving outcomes with a multidisciplinary approach
por: Lo Nigro, Cristiana, et al.
Publicado: (2017)

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
por: Madoz-Gúrpide, Juan, et al.
Publicado: (2015)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy?
por: Yu, Yao, et al.
Publicado: (2021)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Cetuximab in the treatment of head and neck cancer: preliminary results outside clinical trials
por: Dequanter, Didier, et al.
Publicado: (2010)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

Initial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
por: Kurokawa, Marie, et al.
Publicado: (2015)

EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model
por: Gustafsson, H., et al.
Publicado: (2017)

The dogma of Cetuximab and Radiotherapy in head and neck cancer – A dawn to dusk journey
por: Krishnamurthy, Sapna, et al.
Publicado: (2022)

Comprehensive Molecular Landscape of Cetuximab Resistance in Head and Neck Cancer Cell Lines
por: Gomes, Izabela N. F., et al.
Publicado: (2022)

Further Understanding of the Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: Implications for Prognosis
por: Denaro, Nerina, et al.
Publicado: (2021)

Can We Conquer Advanced Head and Neck Cancer? Current Status and Future Directions
por: Won, Ho-Ryun, et al.
Publicado: (2021)

Unusual Fatal Outcome Following Administration of a Combination of anti-PD1 and anti-CTLA4 in Metastatic Renal Cell Carcinoma: Liver Toxicity Case Report and a Literature Review
por: Denaro, Nerina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dis9u2nakgdttijj5fifg9bdpu